US 7,601,363 B2
Sustained-release drug formulations
Akihiko Sano, Toyonaka (Japan); Masako Kajihara, Itami (Japan); and Hiroo Maeda, Sakai (Japan)
Assigned to Dainippon Sumitomo Pharma Co., Ltd., Osaka (Japan)
Filed on Mar. 19, 2007, as Appl. No. 11/688,082.
Application 11/688082 is a continuation of application No. 10/089694, granted, now 7,247,312, previously published as PCT/JP00/07639, filed on Oct. 31, 2000.
Claims priority of application No. 319108/1999 (JP), filed on Nov. 10, 1999.
Prior Publication US 2007/0166377 A1, Jul. 19, 2007
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/14 (2006.01); A61F 2/00 (2006.01); A61F 13/00 (2006.01)
U.S. Cl. 424—422  [424/423; 424/489; 424/490] 6 Claims
 
1. A cured sustained-release formulation for implantation, which comprises one of particle combinations, which is selected from the group consisting of (a), (b) and (c), and a carrier comprising a hydrophobic polymer, wherein the particle combination is dispersed in the carrier:
(a) a particle combination which comprises particles comprising an active ingredient, particles comprising a carbonate, and particles comprising a substance which reacts with the carbonate in an aqueous solution to generate carbon dioxide;
(b) a particle combination which comprises particles comprising an active ingredient and a carbonate, and particles comprising a substance which reacts with the carbonate in an aqueous solution to generate carbon dioxide; and
(c) a particle combination which comprises particles comprising a carbonate, and particles comprising an active ingredient and a substance which reacts with the carbonate in an aqueous solution to generate carbon dioxide; and
wherein
(i) the active ingredient is either slightly soluble or insoluble in water
(ii) the release rate of the active ingredient from the formulation is accelerated in a body fluid, and
(iii) wherein the hydrophobic polymer comprises a non-biodegradable polymer.